Wockhardt Limited

NSEI:WOCKPHARMA Rapporto sulle azioni

Cap. di mercato: ₹190.9b

Wockhardt Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Wockhardt sono diminuiti a un tasso medio annuo di -22.4%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 13.3%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 2.3%.

Informazioni chiave

-22.4%

Tasso di crescita degli utili

-15.9%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore17.5%
Tasso di crescita dei ricavi-2.3%
Rendimento del capitale proprio-7.9%
Margine netto-9.7%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

Nov 02
Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Aug 20
What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jul 27
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Jun 30
Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Jun 22
Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

Feb 21
Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

Dec 19
There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Oct 14
There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Jun 23
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Feb 18
Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jan 04
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Jul 26
Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

May 18
Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Jan 26
Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

Dec 01
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

Ripartizione dei ricavi e delle spese

Come Wockhardt guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NSEI:WOCKPHARMA Ricavi, spese e utili (INR Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 2429,810-2,8806,3080
30 Jun 2429,250-3,4306,3580
31 Mar 2428,300-4,6306,2980
31 Dec 2327,760-5,0106,1700
30 Sep 2327,740-5,1406,1500
30 Jun 2327,000-6,2606,1200
31 Mar 2326,570-5,5906,3800
31 Dec 2226,280-6,1007,0500
30 Sep 2227,820-5,2107,5300
30 Jun 2229,650-2,9807,6800
31 Mar 2232,300-2,4407,5090
31 Dec 2132,074-7877,5960
30 Sep 2131,175-5677,6370
30 Jun 2129,696-8677,8290
31 Mar 2127,080-2,9907,9300
31 Dec 2027,633-1,7808,0410
30 Sep 2024,910-2,5837,1540
30 Jun 2027,167-3,1817,7000
31 Mar 2028,440-1,6387,7040
31 Dec 1935,136-1,3209,5130
30 Sep 1936,903-2,1279,8840
30 Jun 1940,138-1,53310,2750
31 Mar 1935,658-2,8978,9430
31 Dec 1841,851-3,34610,5740
30 Sep 1841,445-3,04310,4090
30 Jun 1840,536-2,8489,4240
31 Mar 1839,245-6,08310,2930
31 Dec 1737,822-6,28510,2610
30 Sep 1737,724-6,41610,4440
30 Jun 1738,148-6,2139,5370
31 Mar 1739,664-1,95710,5420
31 Dec 1641,69548510,3950
30 Sep 1642,4851,74510,3920
30 Jun 1644,1342,49910,4460
31 Mar 1644,5322,50710,3870
31 Dec 1546,0853,16815,201194
30 Sep 1549,1486,03114,960194
30 Jun 1545,4974,9928,9140
31 Mar 1544,8154,0499,4420
31 Dec 1443,8674,45213,521181
30 Sep 1442,4104,02413,332181
30 Jun 1444,6325,3747,9760
31 Mar 1448,3048,40713,899181
31 Dec 1352,77211,01012,6100

Guadagni di qualità: WOCKPHARMA al momento non è redditizia.

Margine di profitto in crescita: WOCKPHARMA al momento non è redditizia.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: WOCKPHARMA non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 22.4% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di WOCKPHARMA nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: WOCKPHARMA non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 20.5% ).


Rendimento del capitale proprio

ROE elevato: WOCKPHARMA ha un Return on Equity negativo ( -7.95% ), in quanto al momento non è redditizio.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate